These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 32382817)
1. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI. Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817 [TBL] [Abstract][Full Text] [Related]
2. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018. Zou X; Luo Y; Morelli JN; Hu X; Shen Y; Hu D Abdom Radiol (NY); 2021 Jul; 46(7):3168-3178. PubMed ID: 33660040 [TBL] [Abstract][Full Text] [Related]
3. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948 [TBL] [Abstract][Full Text] [Related]
4. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Choi SH; Jeon SK; Lee SS; Lee JM; Hur BY; Kang HJ; Kim H; Park Y Eur Radiol; 2021 Dec; 31(12):9479-9488. PubMed ID: 34037829 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Shao S; Liang Y; Kuang S; Chen J; Shan Q; Yang H; Zhang Y; Wang B; J Fowler K; Wang J; B Sirlin C Bosn J Basic Med Sci; 2020 Aug; 20(3):401-410. PubMed ID: 31999940 [TBL] [Abstract][Full Text] [Related]
6. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category. Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745 [TBL] [Abstract][Full Text] [Related]
7. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy. Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906 [No Abstract] [Full Text] [Related]
8. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Lee HS; Kim MJ; An C Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012 [TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397 [TBL] [Abstract][Full Text] [Related]
11. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467 [TBL] [Abstract][Full Text] [Related]
12. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947 [TBL] [Abstract][Full Text] [Related]
13. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170 [TBL] [Abstract][Full Text] [Related]
14. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. Jeon SK; Joo I; Bae JS; Park SJ; Lee JM Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas. Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI. Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990 [TBL] [Abstract][Full Text] [Related]
17. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival? Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018. Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633 [TBL] [Abstract][Full Text] [Related]
19. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI. Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387 [TBL] [Abstract][Full Text] [Related]
20. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017). Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]